Prostatic Acid Phosphatase (PAP) is a glycoprotein enzyme secreted by the prostate gland. It was one of the earliest biomarkers used in the detection and monitoring of prostate cancer, particularly after the association between elevated PAP levels and metastatic prostate cancer was identified in the 1930s.
Today, PAP is primarily used as an adjunct marker rather than a primary screening tool. It is most valuable in assessing advanced prostate cancer, monitoring treatment response, and providing prognostic information when used alongside Prostate-Specific Antigen. In some cases, PAP may be elevated even when PSA levels are normal, helping identify specific disease subtypes or progression patterns.
Compared to PSA, PAP is considered more specific but less sensitive. This means it produces fewer false positives (for example, from benign prostate enlargement), but may miss early-stage disease. Elevated PAP levels are more strongly associated with prostate cancer that has spread beyond the prostate (metastatic disease), making it particularly useful in staging and monitoring.
Clinically, PAP may be ordered in the following contexts:
- Evaluation of suspected advanced prostate cancer
- Monitoring response to prostate cancer treatment
- Assessing disease progression or recurrence
- Complementing PSA testing when results are unclear
Because different laboratory methods can produce varying results, it is important that PAP levels are monitored consistently using the same assay when used for follow-up.
Clinical Notes / Nuances
- PAP is not interchangeable across assays—use the same lab method for monitoring
- More specific than PSA but less sensitive for early detection
- Particularly useful in PSA-negative prostate cancer cases
- Requires proper handling (frozen serum) to ensure accuracy
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.
-
Relative reliability of five serially measured markers for prognosis of progression in prostate cancer